Comparative Analysis of Bipolar Disorder Treatment Guidelines

This chapter provides a comparative analysis of contemporary international clinical practice guidelines for the pharmacotherapy of bipolar disorder, including the Canadian Network for Mood and Anxiety Treatments Guidelines for the Management of Patients with Bipolar Disorder (CANMAT), the International College of Neuro-Psychopharmacology Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD), the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders (RANZCP), and the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP). These guidelines offer recommendations across key clinical situations such as acute mania, depressive episodes, and maintenance treatment. The analysis reveals considerable consensus on several first-line agents. However, notable divergences exist in initial treatment strategies (monotherapy vs. combination therapy), the weighting of efficacy versus safety for specific agents like olanzapine (OLZ), and approaches to subtypes with limited evidence, such as mixed features and rapid cycling. These discrepancies reflect the complexity and evolving nature of bipolar disorder treatment, underscoring the necessity for clinicians to tailor therapeutic choices to individual patient profiles.